The Stop TB Partnership was established in 2000 to realize the goal of eliminating tuberculosis (TB) as a public health problem. It comprises a network of more than 500 international, governmental, nongovernmental and private sector organizations and individuals with an interest in working together to achieve this goal. The Partnership is a global movement to accelerate social and political action to stop the spread of TB around the world. A number of IFPMA members, including AstraZeneca, GlaxoSmithKline, Lilly, Novartis, Pfizer and IFPMA are currently partners of the Stop TB Partnership, and actively contribute to its aims and programs.

The targets set by the Stop Partnership are:

By 2005: 70% of people with infectious TB will be diagnosed and 85% of them cured;

By 2015: the global burden of TB disease will be reduced by 50% relative to 1990 levels (Millennium Development Goal);

By 2050: The global incidence of TB disease will be less than 1 per million population (Elimination of TB as a global public health problem).

The partnership develops advocacy and resource mobilization strategies in support of these priorities, and coordinates and 'brokers' resource flows. In addition, there are six Working Groups that contribute significantly to the achievement of partnership aims: DOTS Expansion Working Group; TB-HIV Working Group; Stop TB Working Group on MDR-TB; Working Group on New TB Drugs, Working Group on New TB Diagnostics and Working Group on New TB Vaccines.

The Stop TB Partnership Private Sector Constituency is the community of businesses with a recognized role or interest in TB control. The Private Sector has been represented on the Coordinating Board of the Global Stop TB Partnership since 2004, following a proposal by the World Economic Forum. The current Board Members are AstraZeneca and Mérieux Alliance.

The Global Drug Facility, run by the Stop TB Partnership, is expanding access to medicines for DOTS scale up; in just 5 years it has committed over 7 million TB treatments. Projects managing MDR-TB can apply through the Green Light Committee (GLC) for access to quality MDR-TB medicines at reduced prices - in some cases by as much as 99%. The Committee is operated by WHO and the Stop TB Partnership. Lilly has a program to make two critical medicines for treatment of drug-resistant strains available in developing countries and will supply 1.4 million vials of capreomycin at concessionary prices to the GLC in 2009. Novartis is donating 500,000 fixed dose combinations to the Global Drug Facility during 2005-2012.